GeneOne Life Science, Inc. (KRX:011000)

South Korea flag South Korea · Delayed Price · Currency is KRW
848.00
-68.00 (-7.42%)
Last updated: Apr 29, 2026, 1:49 PM KST
-61.54%
Market Cap 77.07B
Revenue (ttm) 23.04B
Net Income (ttm) -51.85B
Shares Out 90.67M
EPS (ttm) -629.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,135,026
Average Volume 7,153,184
Open 883.00
Previous Close 916.00
Day's Range 798.00 - 887.00
52-Week Range 618.00 - 4,270.00
Beta 0.69
RSI 43.38
Earnings Date May 14, 2026

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1976
Employees 41
Stock Exchange Korea Stock Exchange
Ticker Symbol 011000
Full Company Profile

Financial Performance

In 2025, GeneOne Life Science's revenue was 23.04 billion, a decrease of -35.49% compared to the previous year's 35.72 billion. Losses were -51.85 billion, 6.83% more than in 2024.

Financial Statements

News

There is no news available yet.